AMZ001 for the Treatment of Knee Osteoarthritis Symptoms

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 4-week trial of a formulation of AMZ001 once or twice daily versus placebo twice daily, including a single-blind treatment group with a commercial gel four times daily.

Timeline

Start

2018-10-04

Primary completion

2019-07-09

Completion

2019-07-09

Drugs

Indications